Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

OSI Pharmaceuticals, Inc. company was founded in 1983 and is based in Melville, New York. OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity. Its flagship product, Tarceva is a small molecule therapeutic designed to inhibit the receptor tyrosine kinase activity of the protein product of the HER1/EGFR gene. The company also offers Novantrone, a mitoxantrone for injection concentrate. OSI Pharmaceuticals products in Phase I clinical trials include OSI-906, an oral small molecule IGF-1R inhibitor for various cancers, including NSCLC, breast, pancreatic, prostate, colorectal, adrenocortical, and ovarian; PSN821, an oral small molecule drug with anti-diabetic and appetite suppressing effects developed for the treatment of type 2 diabetes; PSN602, a novel dual serotonin and noradrenaline reuptake inhibitor for the long-term treatment of obesity; and OSI-027, a small molecule TORC1/TORC2 inhibitor to supersede first generation mTOR inhibitors. The companys other development programs include OSI-296, a novel potent TKI developed to block compensatory signaling in epithelial tumor cells; OSI-930, a multi-targeted tyrosine kinase inhibitor that acts as a potent co-inhibitor of the receptor tyrosine kinases c-kit and the vascular endothelial growth factor receptor-2; OSI-632, an anti-angiogenesis agent; and CP-868,596, a PDGFR inhibitor. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; and AVEO Pharmaceuticals, Inc.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

Nature's Sunshine Products, Inc. company was founded in 1972 and is based in Provo, Utah. Nature's Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide. The company offers herbal products in the form of capsules or tablets; single herbs and herb combinations in the form of liquid herbs and extracts; vitamins and mineral supplements in the form of chewable or non-chewable tablets; personal care products, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser; and various other products, such as nutritional drinks, homeopathic products, and powders. Nature's Sunshine Products sells its products to a sales force of independent distributors and managers, who use the products themselves or resell them to other distributors or consumers. It also exports its products to various countries, including Argentina, Australia, Chile, New Zealand, and Norway.

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and in the area of immunology on allergies, bone loss disorders, Crohn’s disease, rheumatoid arthritis and Systemic lupus erythematosus. UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care. The Company, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. As of December 31, 2008, UCB SA had a number of wholly owned subsidiaries in the United States, Canada, Europe, Asia, South America and Australia.

Martek Biosciences Corporation was founded in 1985 and is headquartered in Columbia, Maryland. Martek Biosciences Corporation engages in the innovation and development of nutritional products from microbial sources, including algae, fungi, and other microbes worldwide. Its products include life'sDHA, a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid) for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements, and animal feeds; and life'sARA, a vegetarian source of the omega-6 fatty acid ARA (arachidonic acid) for use in infant formula. The company also provides contract manufacturing services for the production of enzymes, specialty chemicals, vitamins, and agricultural specialty products. It sells oils containing fatty acids under the names of life'sDHA, DHASCO, Neuromins, ARASCO, and life'sARA. The company markets its nutritional oils primarily to the infant formula, pregnancy and nursing, food and beverage, dietary supplement, and animal feed markets.

Intercytex Limited company is developing cell-based treatments for skin and hair regeneration. Its ICX-TRC product candidate is injected just beneath the scalp to encourage new hair follicles to form. If the candidate wins approval in the US, Intercytex has lined up Bosley Medical Institute, a firm that manages hair transplant clinics across the US, to help distribute its regeneration product. Another product candidate, SHEF-1, could treat age-related macular degeneration. Its ICX-RHY launched in the UK in 2008 under the name Valvelta, as a cosmetic facial rejuvenation product injected transdermally to smoothe out wrinkles.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

Eli Lilly and Company was founded in 1876 and is based in Indianapolis, Indiana. Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. It offers neuroscience products to treat schizophrenia, manic episodes, and bipolar maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; depression, bulimia nervosa, and obsessive-compulsive disorders; and bipolar depression. The company's endocrinology products are used for diabetes; type 2 diabetes; osteoporosis in postmenopausal women; osteoporosis in postmenopausal women and men at high risk for fracture; and human growth hormone deficiency and idiopathic short stature.Eli Lilly and Company also provides oncology products to prevent pancreatic, metastatic breast, non-small cell lung, ovarian, and bladder cancers; malignant pleural mesothelioma; and colorectal cancers, as well as offers cardiovascular products for treating erectile dysfunction, atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention and adults with severe sepsis at high risk of death. In addition, the company offers animal health products, such as cattle feed additives; antibiotics used to treat respiratory diseases and other diseases in cattle, swine, and poultry; protein supplements to improve milk productivity in dairy cows; anticoccidial agents for use in poultry; antibiotics used to control enteric infections in calves and swine; parasiticides for use on cattle and premises; and products that prevents flea infestations on dogs, as well as other pharmaceutical products to treat staphylococcal infections and bacterial infections. Eli Lilly distributes its products principally through independent wholesale distributors, as well as directly to pharmacies. It has a strategic alliance with MacroGenics, Inc.; and licensing and development agreements with TransPharma Medical Ltd. and BioMS Medical Corp.

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.